Dr. Ralph and Marian Falk Medical Research Grant Program

The Dr. Ralph and Marian Falk Medical Research Trust is a private philanthropic funding initiative established in 1979 by Marian Falk to advance biomedical research. The Trust is administered through Bank of America Philanthropic Solutions, with grantmaking operations managed externally by The Medical Foundation, a division of Health Resources in Action. The founding intent of the Trust reflects a long-term commitment to improving medical treatments and ultimately identifying cures for diseases that currently lack definitive solutions. This mission continues to guide all funding priorities and program structures associated with the Trust. The Trust supports medical research through two primary funding mechanisms: the Catalyst Awards Program and the Transformational Awards Program. The Catalyst Awards Program provides seed funding to support early-stage development of research projects. These awards are intended to enable researchers to build foundational elements such as project design, interdisciplinary teams, research tools, methodologies, and management infrastructure. The program accepts applications across basic, preclinical, and clinical research domains, provided that applicants present clear, achievable milestones and measurable deliverables. The Transformational Awards Program serves as a continuation funding mechanism for successful Catalyst Award recipients. Only those who have previously received Catalyst funding are eligible to apply. This program is designed to support more advanced research efforts that address critical scientific or therapeutic challenges. The goal is to help overcome barriers that prevent progress in disease treatment and to open new pathways toward cures. This structured progression from Catalyst to Transformational funding reflects the Trust’s emphasis on sustained, high-impact research development. Funding amounts differ by program. Catalyst Awards provide 400000 dollars in funding for a one-year period, while Transformational Awards provide 500000 dollars distributed over a two-year funding cycle. The funding is intended to support research-related expenses, including personnel, infrastructure, and project development costs. While specific allowable cost categories are not explicitly detailed in the provided materials, the emphasis on research development and execution implies support for core scientific activities. Eligibility is limited and partially invitation-based. Catalyst Awards accept applications only from invited institutions, with a limit of two applications per invited institution per cycle. Transformational Awards are even more restricted, as only current Catalyst Award recipients are eligible to apply. Additionally, while the program serves a broad national scope, special consideration is given to research conducted in the Midwest, including states such as Illinois, Indiana, Iowa, Kansas, Michigan, Missouri, Ohio, Nebraska, North Dakota, South Dakota, and Wisconsin. The application process is administered through The Medical Foundation website. Applicants are directed to consult the HRiA-managed portal for detailed guidelines, application forms, and submission instructions. The application deadline generally occurs in August each year, with guidelines typically released in July for the Catalyst program. Notification of funding decisions is expected in October, and funding for Catalyst Awards begins in November. For inquiries related to the application process, applicants may contact FalkAwards at hria.org, while general foundation inquiries can be directed to the Bank of America contact email. The grant operates on an annual cycle, with recurring opportunities for Catalyst Awards and a structured progression to Transformational Awards. The timeline includes a defined application period, review process, and notification schedule. The externally administered review process ensures an objective evaluation of proposals, though specific evaluation criteria are not detailed in the provided materials. Overall, the Trust represents a focused investment in biomedical innovation, prioritizing research that has the potential to significantly advance disease treatment and cure development.